Dr. Bin Lian 连斌
Chief Physician, Associate Professor
Medical Oncology, Peking University Cancer Hospital, Beijing
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis and treatment of melanoma, sarcoma, renal cancer, and urothelial cancers. Specializes in clinical care and translational research for mucosal melanoma.
Dr. Lian is a Chief Physician and Associate Professor at Peking University Cancer Hospital, holding a PhD from Peking University and having served as a senior visiting scholar at Moffitt Cancer Center. Dr. Lian contributed to national melanoma guidelines and has published first-author papers in journals such as Annals of Oncology and JAMA Oncology. Research findings have been cited by NCCN and ASCO guidelines.
Professional roles
- Secretary-General, CSCO Melanoma Professional Committee
- Standing Committee Member, Beijing Science and Technology Innovation Medical Development Foundation Melanoma Professional Committee
- Member, National Cancer Quality Control Center Melanoma Quality Control Professional Committee
- Member, China Medicine Education Association Tumor Clinical Research Innovation and Development Professional Committee
Name order: in Chinese the family name comes first (Lian Bin). Papers usually list the name as Bin Lian or Lian B.
Selected publications
82 papers on PubMed matched by name and affiliation; 3 as first or senior author since 2016. Most recent first- or senior-author papers:
- Am Soc Clin Oncol Educ Book, 2025 (first author): Therapeutic Approaches to Mucosal Melanoma. PubMed 40435430
- Int J Radiat Oncol Biol Phys, 2024 (first author): Efficacy and Safety of Postoperative Adjuvant Radiation Therapy in Resected Nasal Cavity and Paranasal Sinus Mucosal Melanoma: A Combined Analysis. PubMed 38522768
- Innovation (Camb), 2024 (senior author): IBI310 (anti-CTLA-4 antibody) monotherapy or in combination with sintilimab in advanced melanoma or urothelial carcinoma. PubMed 38881798
- Chin Clin Oncol, 2014 (first author): Checkpoint inhibitors in treatment of metastatic mucosal melanoma. PubMed 25841463
- Chin Clin Oncol, 2014 (first author): Adjuvant therapy of mucosal melanoma. PubMed 25841459
- Clin Cancer Res, 2013 (first author): Phase II randomized trial comparing high-dose IFN-α2b with temozolomide plus cisplatin as systemic adjuvant therapy for resected mucosal melanoma. PubMed 23833309
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers; we checked the papers' affiliations and topics against this doctor's department.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion